Health & Biotech
‘Monumental’– Bioxyne subsidiary awarded Australia’s first GMP licence to manufacture psilocybin and MDMA
Health & Biotech
ASX Health Stocks: LTP is recruiting for patients to try its erection spray
Health & Biotech
How big-hearted EBR Systems is pacing a multi-billion dollar cardiac market
Health & Biotech
Why the buzz for kava is growing, and how The Calmer Co. is capitalising
Health & Biotech
ASX Health Stocks: Radiopharm’s results published; ProMedicus launches on Apple Vision Pro
Health & Biotech
Dr Boreham’s Crucible: ResMed holders breathe easy – those fat-busting needles have only hurt a little bit
Health & Biotech
ASX Health Stocks: Singular Health shoots 60pc through the roof after breakthrough deal in US
Health & Biotech
ASX Health Winners January: ‘Invest in business not science’, as SHG and PAA top winners list
Health & Biotech
ASX Health Stocks: NSB jumps 11pc after quarterly update; Lumos makes great strides with FDA
Health & Biotech
ASX Health Stocks: A breakthrough for CAR T therapy? Arovella signs deal to advance CAR-iNKT platform
Health & Biotech
PharmAust gets ethics committee green light for open-label MND extension study
Health & Biotech
Neurotech gets green light to start phase I/II cerebral palsy trial
Featured Health & Biotech Stocks
Health & Biotech
Healthcare stocks are as varied as the solutions they are working to solve. The sector covers biotech stocks developing breakthrough pharmaceutical drugs and vaccines to medtech companies launching the latest and greatest medical devices they hope will change the face of healthcare.
Even the ‘budding’ medical cannabis industry is in the mix as researchers explore new applications and treatments.
If you want to know what’s happening with emerging health stocks on the ASX, Stockhead has you covered, with daily stock news, expert insight and research. You can also recap broader industry trends and recent share price movements across the sector in our regular ‘Check Up’ feature.
Accurate, up-to-date news stories are important, especially in the health sector where progress is often slow and risk often high. That’s why we’re focused on helping small cap investors make sense of the medical jargon.